ICON plc (ICLR)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
- Symbol
- ICLR
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Market cap
- $12.89B
- 52 week range
- 66.57 - 203.91
Valuation
- Share price
- $163.90 (close of 2026-09-23)
- P/E (TTM)
- 253.20x
- Price to book
- 1.37x
- Price to free cash flow
- 14.59x
- Enterprise value
- $15.46B
- Book value per share
- $121.55
Price performance
| Period | Change |
|---|
| 1 day | -3.33% |
| 5 days | -4.96% |
| 1 month | -4.84% |
| 3 months | +14.88% |
| 6 months | +63.33% |
| Year to date | -10.05% |
| 1 year | -3.80% |
| 3 years | -34.55% |
| 5 years | -41.77% |
| 10 years | +114.30% |
| All time | +2477.04% |
Profitability and growth
- Return on equity
- 2.49%
- Return on invested capital
- 3.47%
- Return on assets
- 1.41%
- Return on capital employed
- 3.39%
- Gross margin
- 14.82%
- Net margin
- 2.78%
- EBITDA margin
- 10.01%
- Revenue growth
- 0.76%
- Net income growth
- -68.97%
- Free cash flow growth
- -22.94%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 6.85%
- Current ratio
- 0.95x
- Net debt to EBITDA
- 6.65x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $8.25B
- Cost of revenue
- $7.03B
- Gross profit
- $1.22B
- EBITDA
- $825.84M
- Net income
- $229.34M
- Earnings per share
- $2.92
- Shares outstanding
- 78.42M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $8.25B | $1.22B | $229.34M | $2.92 |
| 2024-12-31 | $8.19B | $2.34B | $739.13M | $8.96 |
| 2023-12-31 | $8.05B | $2.33B | $554.21M | $6.75 |
| 2022-12-31 | $7.74B | $2.21B | $505.30M | $6.20 |
| 2021-12-31 | $5.48B | $1.51B | $153.19M | $2.28 |
| 2020-12-31 | $2.80B | $817.40M | $332.33M | $6.20 |
| 2019-12-31 | $2.81B | $831.70M | $373.99M | $6.85 |
| 2018-12-31 | $2.60B | $777.56M | $322.66M | $5.96 |
| 2017-12-31 | $1.76B | $731.13M | $281.49M | $5.20 |
| 2016-12-31 | $1.67B | $705.15M | $262.18M | $4.75 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 14.82% | 2.78% | 2.49% | 3.47% |
| 2024-12-31 | 28.62% | 9.03% | 7.83% | 7.74% |
| 2023-12-31 | 28.99% | 6.88% | 6.02% | 6.94% |
| 2022-12-31 | 28.60% | 6.53% | 5.93% | 5.63% |
| 2021-12-31 | 27.52% | 2.79% | 1.90% | 2.61% |
| 2020-12-31 | 29.22% | 11.88% | 17.96% | 23.80% |
| 2019-12-31 | 29.64% | 13.33% | 23.11% | 33.15% |
| 2018-12-31 | 29.95% | 12.43% | 23.82% | 34.58% |
| 2017-12-31 | 41.58% | 16.01% | 23.63% | 32.13% |
| 2016-12-31 | 42.31% | 15.73% | 27.74% | 36.37% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $647.29M | $2.87B |
| 2024-12-31 | $538.78M | $3.40B |
| 2023-12-31 | $378.10M | $3.67B |
| 2022-12-31 | $288.77M | $4.60B |
| 2021-12-31 | $752.21M | $5.38B |
| 2020-12-31 | $840.30M | $348.48M |
| 2019-12-31 | $569.90M | - |
| 2018-12-31 | $395.85M | - |
| 2017-12-31 | $282.86M | - |
| 2016-12-31 | $192.54M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $861.99M | $102.04M |
| 2024-12-31 | $1.12B | $45.87M |
| 2023-12-31 | $1.02B | $55.67M |
| 2022-12-31 | $421.15M | $70.52M |
| 2021-12-31 | $735.39M | $133.84M |
| 2020-12-31 | $527.15M | $26.27M |
| 2019-12-31 | $373.59M | $26.82M |
| 2018-12-31 | $220.24M | $31.59M |
| 2017-12-31 | $338.37M | $30.57M |
| 2016-12-31 | $216.60M | $40.34M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-28
- Consensus EPS estimate
- $2.44
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-29 | Jun/2026 | $2.26 |
| 2026-06-23 | Mar/2026 | $2.16 |
| 2026-05-27 | - | - |
| 2025-10-22 | - | - |
| 2025-07-23 | - | - |
| 2025-04-30 | - | - |
| 2025-02-19 | - | - |
| 2024-10-23 | - | - |
Filings and sources
- Company website
- iconplc.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV) · Agilent Technologies, Inc. (A) · Waters Corp (WAT) · IDEXX Laboratories Inc (IDXX) · Mettler-Toledo International Inc (MTD) · Quest Diagnostics Inc (DGX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades